HIV Testing Preferences and Characteristics of Those Who Have Never Tested for HIV in the United States.


Journal

Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941

Informations de publication

Date de publication:
01 03 2023
Historique:
pubmed: 3 2 2023
medline: 9 2 2023
entrez: 2 2 2023
Statut: ppublish

Résumé

The initial phase of the federal Ending the HIV Epidemic in the U.S. (EHE) initiative prioritized efforts in 57 geographic areas. The US Centers for Disease Control and Prevention recommends persons aged 13 to 64 years be tested for HIV at least once as part of routine health care; however, it is unclear how effectively these testing recommendations have been implemented in EHE priority areas. In 2021 to 2022, we analyzed data from a Web-based, nationally representative survey of adults fielded in 2021. HIV testing preferences were compared by testing history, demographic characteristics, behaviors, and geography. An estimated 72.5% of US adults had never tested for HIV. Never testing was most prevalent among those aged 18 to 29 or those 50 years or older, non-Hispanic White persons, and those living in the Midwest. Among persons living in EHE priority areas and persons reporting at least one behavior that increases risk of HIV transmission, 69.1% and 48.0%, respectively, had never tested for HIV. The top 3 HIV testing preferences among never testers were as follows: testing for HIV during a routine health care visit (41.2%), testing at an urgent care or walk-in clinic (9.6%), and self-testing (8.1%). Most adults had not been tested for HIV, confirming that US Centers for Disease Control and Prevention recommendations are not being fully implemented, even in EHE priority areas. Moreover, most adults who never tested preferred testing in clinical settings, highlighting missed opportunities. As the EHE initiative continues to advance, it is critical to leverage preferred HIV testing modalities, such as routine testing in clinical settings or HIV self-testing.

Sections du résumé

BACKGROUND
The initial phase of the federal Ending the HIV Epidemic in the U.S. (EHE) initiative prioritized efforts in 57 geographic areas. The US Centers for Disease Control and Prevention recommends persons aged 13 to 64 years be tested for HIV at least once as part of routine health care; however, it is unclear how effectively these testing recommendations have been implemented in EHE priority areas.
METHODS
In 2021 to 2022, we analyzed data from a Web-based, nationally representative survey of adults fielded in 2021. HIV testing preferences were compared by testing history, demographic characteristics, behaviors, and geography.
RESULTS
An estimated 72.5% of US adults had never tested for HIV. Never testing was most prevalent among those aged 18 to 29 or those 50 years or older, non-Hispanic White persons, and those living in the Midwest. Among persons living in EHE priority areas and persons reporting at least one behavior that increases risk of HIV transmission, 69.1% and 48.0%, respectively, had never tested for HIV. The top 3 HIV testing preferences among never testers were as follows: testing for HIV during a routine health care visit (41.2%), testing at an urgent care or walk-in clinic (9.6%), and self-testing (8.1%).
CONCLUSIONS
Most adults had not been tested for HIV, confirming that US Centers for Disease Control and Prevention recommendations are not being fully implemented, even in EHE priority areas. Moreover, most adults who never tested preferred testing in clinical settings, highlighting missed opportunities. As the EHE initiative continues to advance, it is critical to leverage preferred HIV testing modalities, such as routine testing in clinical settings or HIV self-testing.

Identifiants

pubmed: 36729993
doi: 10.1097/OLQ.0000000000001746
pii: 00007435-202303000-00010
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

175-179

Informations de copyright

Copyright © 2022 American Sexually Transmitted Diseases Association. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest and Sources of Funding: None declared.

Références

Centers for Disease Control and Prevention. HIV Surveillance Report. 2019; 32. Available at: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html . Published May 2021. Accessed July 20, 2022.
Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2015–2019. HIV Surveill Suppl Rep 2021; 26. Available at: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html . Published May 2021. Accessed July 20, 2022.
Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55(RR-14):1–17.
The White House. National HIV/AIDS Strategy for the United States 2022–2025. Washington, DC: The White House, 2021. Available at: https://www.whitehouse.gov/wp-content/uploads/2021/11/National-HIV-AIDS-Strategy.pdf . Accessed May 24, 2022.
Fauci AS, Redfield RR, Sigounas G, et al. Ending the HIV Epidemic: A plan for the United States. JAMA 2019; 321:844–845.
Collins B, Bronson H, Elamin F, et al. The “No Wrong Door” approach to HIV testing: Results from a statewide retail pharmacy-based HIV testing program in Virginia, 2014–2016. Public Health Rep 2018; 133(suppl 2):34S–42S.
Hecht J, Sanchez T, Sullivan PS, et al. Increasing access to HIV testing through direct-to-consumer HIV self-test distribution—United States, March 31, 2020–March 30, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1322–1325.
Porter Novelli. ConsumerStyles & YouthStyles. 2021. Available at: http://styles.porternovelli.com/consumer-youthstyles/ . Accessed January 12, 2022.
Yeager DS, Krosnick JA, Chang LC, et al. Comparing the accuracy of RDD telephone surveys and Internet surveys conducted with probability and non-probability samples. Public Opin Q 2011; 75:709–747.
BRFSS Questionnaires. Available at: https://www.cdc.gov/brfss/questionnaires/index.htm . Accessed November 8, 2022.
Centers for Disease Control and Prevention. Ending the HIV Epidemic in the U.S. (EHE). Available at: https://www.cdc.gov/endhiv/jurisdictions.html . Accessed March 16, 2022.
Pitasi MA, Delaney KP, Brooks JT, et al. HIV testing in 50 local jurisdictions accounting for the majority of new HIV diagnoses and seven states with disproportionate occurrence of HIV in rural areas, 2016–2017. MMWR Morb Mortal Wkly Rep 2019; 68:561–567.
Carey JW, Courtenay-Quirk C, Carnes N, et al. HIV testing program activities and challenges in four U.S. urban areas. AIDS Educ Prev 2022; 34:99–115.
Gebrezgi MT, Mauck DE, Sheehan DM, et al. Acceptance of opt-out HIV screening in outpatient settings in the United States: A systematic review and meta-analysis. Public Health Rep 2019; 134:484–492.
Chavez PR, Emerson B, Lilo E, et al. CDC's direct-to-consumer distribution of 100,000 HIV self-tests. Oral Presentation. 2022 Advancing HIV, STI and Viral Hepatitis Testing Conference March 2022. Available at: https://hivtestingconference.org/wp-content/uploads/2022/04/Chavz_B3Session3.pdf . Accessed July 20, 2022.

Auteurs

Shilpa N Patel (SN)

From the Division of HIV Prevention, Centers for Disease Control and Prevention.

Brian P Emerson (BP)

From the Division of HIV Prevention, Centers for Disease Control and Prevention.

Marc A Pitasi (MA)

From the Division of HIV Prevention, Centers for Disease Control and Prevention.

Natalie E Tripp (NE)

DLH Corp., Atlanta, GA, assigned to the Division of HIV Prevention at the Centers for Disease Control and Prevention.

Ruthanne Marcus (R)

From the Division of HIV Prevention, Centers for Disease Control and Prevention.

Kevin P Delaney (KP)

From the Division of HIV Prevention, Centers for Disease Control and Prevention.

Pollyanna R Chavez (PR)

From the Division of HIV Prevention, Centers for Disease Control and Prevention.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH